The China Stroke Secondary Prevention Trial (CSSPT) Protocol: A Double-Blinded,Randomized,Controlled Trial of Combined Folic Acid and B Vitamins for Secondary Prevention of Stroke

Abstract

Rationale

Epidemiological studies suggest that elevated homocysteine is linked to stroke and heart disease. However, the results of lowering homocysteine levels in reducing the risk of stroke recurrence are controversial.

Aims

The study aims to evaluate whether homocysteine-lowering therapy with folic acid and vitamins B₆ and B₁₂ reduces recurrent stroke events and other combined incidence of recurrent vascular events and vascular death in ischemic stroke patients of low folate regions.

Design

This is a multicenter, randomized, double-blinded, placebo-controlled trial. Patients (n = 8000, α = 0·05, β = 0·10) within one-month of ischemic stroke (large-artery atherosclerosis or small-vessel occlusion) or hypertensive intracerebral haemorrhage with plasma homocysteine level ⩾15 μmol/l will be enrolled. Eligible patients will be randomized by a web-based, random allocation system to receive multivitamins (folic acid 0·8 mg, vitamin B₆10 mg, and vitamin B12 500 μg) or matching placebo daily with a median follow-up of three-years.

Study Outcomes

Patients will be evaluated at six monthly intervals. The primary outcome event is the composite event ‘stroke, myocardial infarction, or death from any vascular cause’, whichever occurs first. Secondary outcome measures include nonvascular death, transient ischemic attack, depression, dementia, unstable angina, revascularization procedures of the coronary, and cerebral and peripheral circulations.

Discussion

This is the first multicenter randomized trial of secondary prevention for ischemic stroke in a Chinese population with a higher homocysteine level but without folate food fortification.

Keywords

folate homocysteine randomized clinical trial stroke prevention

Get full access to this article

View all access options for this article.

References

Goldstein

Adams

Alberts

. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2006; 113:e873–923.

Liu

Zhang

Yin

. Recurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable risk factors. Cerebrovasc Dis 2007; 23:117–20.

Christen

Ajani

Glynn

Hennekens

. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160:422–34.

Lentz

. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3:1646–54.

Khan

Crossley

Kalra

. Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke 2008; 39:2943–9.

Cui

Moriyama

Koike

. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis 2008; 198:412–8.

Wald

Law

Morris

. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.

Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015–22.

Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82:806–12.

10.

Till

Rohl

Jentsch

. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis 2005; 181:131–5.

11.

Vermeulen

Stehouwer

Valk

. Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial. Eur J Clin Invest 2004; 34:256–61.

12.

Vermeulen

Stehouwer

Twisk

. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000; 355:517–22.

13.

Toole

Malinow

Chambless

. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565–75.

14.

Bonaa

Njolstad

Ueland

. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578–88.

15.

Lonn

Yusuf

Arnold

. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567–77.

16.

VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010; 9:855–65.

17.

Wang

Qin

Demirtas

. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876–82.

18.

Saposnik

Ray

Sheridan

McQueen

Lonn

. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009; 40:1365–72.

19.

Eikelboom

Hankey

Anand

Lofthouse

Staples

Baker

. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31:1069–75.

20.

Zhang

Sun

Chen

. High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. Clin Sci (Lond) 2010; 118:187–94.

21.

Yang

Botto

Gallagher

. Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank. Am J Clin Nutr 2008; 88:232–46.

22.

Sun

Zhang

. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke 2003; 34:2085–90.

23.

Holmes

Newcombe

Hubacek

. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011; 378:584–94.

24.

Adams

Bendixen

Kappelle

. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35–41.

25.

Cai

Xia

Gao

Yan

. A generic minimization random allocation and blinding system on web. J Biomed Inform 2006; 39: 706–19.

26.

Windelberg

Arseth

Kvalheim

Ueland

. Automated assay for the determination of methylmalonic acid, total homocysteine, and related amino acids in human serum or plasma by means of methylchloroformate derivatization and gas chromatography-mass spectrometry. Clin Chem 2005; 51:2103–9.

27.

Kelleher

Broin

. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. J Clin Pathol 1991; 44:592–5.

28.

Molloy

Scott

. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods Enzymol 1997; 281:43–53.

29.

Frosst

Blom

Milos

. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111–3.

30.

Easton

Saver

Albers

. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40:2276–93.